Edaravone for treatment of early-stage ALS - Authors' reply

Lancet Neurol. 2017 Oct;16(10):772. doi: 10.1016/S1474-4422(17)30290-9. Epub 2017 Sep 12.

Authors

Makoto Akimoto¹, Kazue Nakamura²; Writing Group on behalf of the Edaravone (MCI-186) ALS 19 Study Group

Affiliations

¹ Clinical Planning Department I, Ikuyaku. Integrated Value Development Division, Mitsubishi Tanabe Pharma Corporation, Tokyo 103-8405, Japan. Electronic address: akimoto.makoto@mc.mt-pharma.co.jp.
² Clinical Planning Department I, Ikuyaku. Integrated Value Development Division, Mitsubishi Tanabe Pharma Corporation, Tokyo 103-8405, Japan.

PMID: 28920878
DOI: 10.1016/S1474-4422(17)30290-9

No abstract available

Publication types

Letter
Comment

MeSH terms

Amyotrophic Lateral Sclerosis*
Antipyrine* / analogs & derivatives
Edaravone
Free Radical Scavengers
Humans

Substances

Free Radical Scavengers
Edaravone
Antipyrine

Supplementary concepts

Amyotrophic Lateral Sclerosis 2, Juvenile